An example of our successful out-licensing strategy in the diagnostics field are our agreements with Labco Quality Diagnostics and Diacarta to launch our non-invasive test to detect genetic material in circulating-free DNA (cfDNA) in serum and plasma of cancer patients. LABCO is the largest DX provider in Europe and has significant presence in Latin America while Diacarta will commercialize our liquid biopsy assay in the U.S.A and China.
LABCO and PANGAEA launch a non-invasive test for monitoring cancer treatment
DiaCarta and Pangaea Biotech Join Forces to Launch Non-Invasive Tests to Detect Genetic Mutations in Blood from Cancer Patients
We focus on reaching agreements with companies which have:
Wide distribution capabilities
A clear focus on new emerging technologies and novel content
We are actively pursuing an innovative Drug Development program focusing on first-in-class or best-in-class new chemical entities for cancer indications with high unmet needs and are open to collaboration at any stage of pre-clinical and clinical development.
For further details of out-licensing opportunities: Contact us